MicroRNA profiling of a CD133+ spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Nam, Eun Ji ^a   Lee, Maria ^a   Yim, Ga Won ^a   Kim, Jae Hoon ^a   Kim, Sunghoon ^a   Kim, Sang Wun ^a   Kim, Young Tae ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cancer stem cell; CD133; Chemoresistance; MicroRNA; Ovarian cancer; OVCAR3

Indexed keywords

CD133 ANTIGEN; MICRORNA; MICRORNA 1181; MICRORNA 1202; MICRORNA 146A; MICRORNA 200A; MICRORNA 200B; MICRORNA 205; MICRORNA 3; PACLITAXEL; RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CELL ANCHORAGE; CELL GROWTH; CELL SELECTION; CELL SUBPOPULATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EVALUATION RESEARCH; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPHEROID CELL; TUMOR SPHEROID; UPREGULATION;

ANTIGENS, CD; BLOTTING, WESTERN; CELL PROLIFERATION; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; PEPTIDES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84861466680     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-18     Document Type: Article

References (27)

1. Current management of epithelial ovarian carcinoma: a review. Marsden DE, Friedlander M, Hacker NF, Semin Surg Oncol 2000 19 1 11 19 10.1002/1098- 2388(200007/08)19:1<11::AID-SSU3>3.0.CO;2-3 10883019
2. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM, Cancer Res 2006 66 19 9339 9344 10.1158/0008-5472.CAN-06-3126 16990346
3. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN, Nature 2006 444 7120 756 760 10.1038/nature05236 17051156
4. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Bonnet D, Dick JE, Nat Med 1997 3 7 730 737 10.1038/nm0797-730 9212098
5. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG, Cancer Res 2005 65 13 5506 5511 10.1158/0008-5472.CAN-05-0626 15994920
6. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Bapat SA, Mali AM, Koppikar CB, Kurrey NK, Cancer Res 2005 65 8 3025 3029 15833827
7. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R, Stem Cells 2009 27 12 2875 2883 19816957
8. RNA interference. Hannon GJ, Nature 2002 418 6894 244 251 10.1038/418244a 12110901
9. Liver stem cells and hepatocellular carcinoma. Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP, Hepatology 2009 49 1 318 329 10.1002/hep.22704 19111019
10. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Wu Q, Guo R, Lin M, Zhou B, Wang Y, Gynecol Oncol 2011 122 1 149 154 10.1016/j.ygyno.2011.03.026 21529905
11. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G, Oncogene 2010 29 24 3545 3553 10.1038/onc.2010.111 20400975
12. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Guo R, Wu Q, Liu F, Wang Y, Oncol Rep 2011 25 1 141 146 21109969
13. Neurosphere and neurosphere-forming cells: morphological and ultrastructural characterization. Bez A, Corsini E, Curti D, Biggiogera M, Colombo A, Nicosia RF, Pagano SF, Parati EA, Brain Res 2003 993 1-2 18 29 14642827
14. Cancer stem cells: models and concepts. Dalerba P, Cho RW, Clarke MF, Annu Rev Med 2007 58 267 284 10.1146/annurev.med.58.062105.204854 17002552
15. Expression of CD133-1 and CD133-2 in ovarian cancer. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G, Int J Gynecol Cancer 2008 18 3 506 514 10.1111/j.1525-1438.2007.01056.x 17868344
16. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA, Nat Genet 2008 40 5 499 507 10.1038/ng.127 18443585
17. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA, Cancer Cell 2007 12 2 160 170 10.1016/j.ccr.2007.06.013 17692807
18. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Chen J, Wang L, Matyunina LV, Hill CG, McDonald J, Gynecol Oncol 121 1 200 205
19. Micro-RNA profiling in kidney and bladder cancers. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R, Urol Oncol 2007 25 5 387 392 10.1016/j.urolonc.2007.01.019 17826655
20. The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. Greene SB, Herschkowitz JI, Rosen JM, RNA Biol 7 3 300 304
21. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B, Cell Death Dis 2010 1 105 10.1038/cddis.2010.85 21368878
22. MicroRNA-146a disrupts hematopoietic differentiation and survival. Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL, Humphries RK, Karsan A, Exp Hematol 2011 39 2 167 178 e164 10.1016/j.exphem. 2010.09.011 20933052
23. miR-146a suppresses invasion of pancreatic cancer cells. Li Y, 2nd Vandenboom TG, Wang Z, Kong D, Ali S, Philip PA, Sarkar FH, Cancer Res 2010 70 4 1486 1495 10.1158/0008-5472.CAN-09-2792 20124483
24. MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Paik JH, Jang JY, Jeon YK, Kim WY, Kim TM, Heo DS, Kim CW, Clin Cancer Res 2011 17 14 4761 4771 10.1158/1078-0432.CCR-11-0494 21610143
25. Functional roles of Src and Fgr in ovarian carcinoma. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala L, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK, Clin Cancer Res 2011 17 7 1713 1721 10.1158/1078-0432.CCR-10-2081 21300758
26. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Smith JA, Ngo H, Martin MC, Wolf JK, Gynecol Oncol 2005 98 1 141 145 10.1016/j.ygyno.2005.02.006 15963813
27. Comprehensive miRNA profiling of surgically staged endometrial cancer. Cohn DE, Fabbri M, Valeri N, Alder H, Ivanov I, Liu CG, Croce CM, Resnick KE, Am J Obstet Gynecol 2010 202 6 656 e651-658 20400061